The Basics
What is Iodohippurate Sodium I 123?
Commonly used for evaluating effective renal plasma flow (ERPF) by means of either in vivo scintigraphy and/or plasma clearance curves.
Brand names for Iodohippurate Sodium I 123
Na
How Iodohippurate Sodium I 123 is classified
Radiopharmaceuticals, Iodine Radioisotopes, Diagnostic Agents
Iodohippurate Sodium I 123 During Pregnancy
Iodohippurate Sodium I 123 pregnancy category
Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.
What we know about taking Iodohippurate Sodium I 123 while pregnant
N/A
Taking Iodohippurate Sodium I 123 While Breastfeeding
What are recommendations for lactation if you're taking Iodohippurate Sodium I 123?
Information in this record refers to the use of iodohippurate sodium I 123 (I 123 ortho-iodohippurate; I 123 OIH) as a kidney function diagnostic agent. The United States Nuclear Regulatory Commission states that breastfeeding need not be interrupted after administration of I 123 OIH in doses up to 100 MBq (4 mCi) to a nursing mother.[1] However, some experts recommend nursing the infant just before administration of the radiopharmaceutical and interrupting breastfeeding for 8 to 12 hours after the dose.[2][3][4] If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[2][5] Mothers need not refrain from close contact with their infants after usual clinical doses.[6] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[7]
Maternal / infant drug levels
Information in this record refers to the use of iodohippurate sodium I 123 (I 123 ortho-iodohippurate; I 123 OIH) as a kidney function diagnostic agent. The United States Nuclear Regulatory Commission states that breastfeeding need not be interrupted after administration of I 123 OIH in doses up to 100 MBq (4 mCi) to a nursing mother.[1] However, some experts recommend nursing the infant just before administration of the radiopharmaceutical and interrupting breastfeeding for 8 to 12 hours after the dose.[2][3][4] If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[2][5] Mothers need not refrain from close contact with their infants after usual clinical doses.[6] Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[7]
Possible effects of Iodohippurate Sodium I 123 on milk supply
Relevant published information was not found as of the revision date.
Possible alternatives to Iodohippurate Sodium I 123
None listed
List of References
Lactation sources: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/1. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/
2. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15-27. PMID: 2645546
3. Mattsson S, Johansson L, Leide Svegborn S et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP. 2015;44 (2 Suppl):319-21. PMID: 26069086
4. International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, IAEA, Vienna. 2018. https://www.iaea.org/publications/11102/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation
5. National Radiation Protection Board (UK). Administration of radioactive substances advisory committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2019. https://assets.publishing.service.gov.uk/government/…/file/…/ARSAC_NfG_2019.pdf
6. Mountford PJ, O’Doherty MJ. Exposure of critical groups to nuclear medicine patients. Appl Radiat Isot. 1999;50:89-111. PMID: 10028630
7. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203
Disclaimer: This material is provided for educational purposes only and is not intended for medical advice, diagnosis, or treatment. Consult your healthcare provider with any questions.
